VEGFA and retinopathy of prematurity: Thus, A2AR antagonism may represent novel and promising pharmacological strategy to control retinal pathological angiogenesis in ROP with distinct advantage over other anti-VEGF antibody strategies, which may be necessary not only for pathological angiogenesis, but also for normal retinal vascularization and brain development (LeBlanc et al. 2013).